Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£135.46 -20.00 (-0.15%)
As of 08:31 AM Eastern
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings
Sell
1
Hold
0
Buy
5

Based on 6 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a sell rating, and 5 have given a buy rating for AZN.

Consensus Price Target

£153.33
According to the 6 analysts' twelve-month price targets for AstraZeneca, the average price target is £153.33. The highest price target for AZN is £180, while the lowest price target for AZN is £115. The average price target represents a forecasted upside of 13.19% from the current price of £135.46.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
5/7/25 to 5/7/26		1 Month Ago
4/7/25 to 4/7/26		3 Months Ago
2/6/25 to 2/6/26		1 Year Ago
5/7/24 to 5/7/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£153.33£145.83£145.83GBX 6,303.50
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical Companies
Consensus Rating Score
2.67
2.30
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
5/6/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Reiterated RatingSell£115 ➝ £115-15.29%
4/10/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy£180 ➝ £180+16.94%
4/10/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
 Boost TargetBuy£170 ➝ £180+16.94%
1/27/2026
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy£145 ➝ £160+17.94%
1/16/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/15/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:27 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 6, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • The current stock price is around £149.89, which is above its 200-day moving average, indicating a potential upward trend in value.
  • Recent upgrades from analysts, including a target price increase to £180 by Citigroup, suggest strong future performance and investor confidence.
  • AstraZeneca PLC has a solid market capitalization of approximately £238.70 billion, reflecting its stability and growth potential in the biopharmaceutical sector.
  • The company has received multiple "buy" ratings from various analysts, indicating a consensus that the stock is a favorable investment opportunity.
  • AstraZeneca PLC is actively involved in innovative medicine development, focusing on critical therapy areas such as Oncology and Cardiovascular health, which are in high demand.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • Despite positive ratings, there is a "sell" rating from Deutsche Bank, indicating some analysts have concerns about the stock's future performance.
  • The company has a relatively high debt-to-equity ratio of 60.87, which may raise concerns about financial leverage and risk.
  • Market volatility can impact AstraZeneca PLC's stock price, as seen in fluctuations around its moving averages.
  • While the stock has shown recent strength, it is essential to consider that the biopharmaceutical sector can be unpredictable due to regulatory changes and competition.
  • Investors should be cautious of the company's P/E ratio of 23.54, which may suggest that the stock is overvalued compared to its earnings potential.

AZN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £153.33, with a high forecast of £180 and a low forecast of £115.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 13.19% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, and Jefferies Financial Group in the past 90 days.

Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how AZN compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations


This page (LON:AZN) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel